U.S. Public Law 110-85 (Food and Drug Administration Amendments Act of 2007 or FDAAA), Title VIII, Section 801 mandates that a "responsible party" (i.e., the sponsor or designated principal investigator) register and report results of certain "applicable clinical trials": "Applicable clinical trials" generally include interventional studies (with one or more arms) of drugs, biological products, or devices that are subject to FDA regulation, meaning that the trial has one or more sites in the U.S, involves a drug, biologic, or device that is manufactured in the US (or its territories), or is conducted under an investigational new drug application (IND) or investigational device exemption (IDE). For the complete statutory definitions and more detailed information on the agency's current thinking about their meaning, see this pdf document.

• May 21, 2008 Federal Register Notice - describes the public process for the expansion of ClinicalTrials.gov under FDAAA 801 (pdf).
• Certification of Compliance to FDA - to accompany Drug, Biological Product, and Device applications or submissions
• Statement on Pediatric Postmarket Surveillance of Devices - Pediatric postmarket surveillance of devices ordered under section 522 of the Federal Food, Drug and Cosmetic Act must be registered at ClinicalTrials.gov in accordance with the provisions of Section 801 of FDAAA (see NIH Fact Sheet (10/27/09)). Please contact register@clinicaltrials.gov to determine the best mechanism for using ClinicalTrials.gov to address this provision.

Data Submission

Investigators or Sponsors who already have PRS accounts should log into the PRS for the latest information. Others who anticipate needing to register studies in ClinicalTrials.gov in accordance with the provisions of Section 801 of FDAAA should request a PRS account using the instructions provided under Account Application Process.

Expanded Registry

• Data Element Definitions (DRAFT) - details on the information that is entered via the PRS
• NIH Fact Sheet (10/27/09) on registration at ClinicalTrials.gov under FDAAA 801
• The NIH Office of Extramural Research has information for NIH awardees.

"Basic Results" Database

• Adverse Event Reporting - information on the requirements for reporting adverse events
• Guide to Results Data Entry - (CHEST, 2009 Jul;136(1):295-303) - article includes summary results reporting requirements, brief descriptions of the results database modules, and suggestions for preparing results submissions
• Pre-Submission Checklist (pdf) (DRAFT) - a short reminder checklist to assist in results data entry
• Common errors (pdf) (DRAFT) - overview of common types of errors identified in submitted records with "basic results"
• Helpful hints (pdf) - tips on entering results data, including three examples of common study models (parallel design, crossover design, and diagnostic accuracy studies), reporting measure types, including information on reporting outcomes measured with a scale.
• "Basic Results" Data Element Definitions (DRAFT) - details on the information that is entered about results, including adverse events, via the PRS.
• Detailed Review Items (pdf) (DRAFT) - describes items evaluated by ClinicalTrials.gov after results have been submitted.
• Basic Results Provisions (pdf) - extracted from FDAAA 801.
• Delayed Submission of Results - information on submitting certifications or requests for extension
• Recorded Presentation (Adobe Flash: 37 minutes) and accompanying slides (pdf)
  • Module 1: ClinicalTrials.gov Overview and PL 110-85 Requirements
  • Module 2: "Basic Results" Data Entry
  • Module 3: Posted Results at ClinicalTrials.gov

Public Meeting - April 20, 2009

• Section 801 of U.S. Public Law 110-85 directs the Secretary of Health and Human Services to hold a public meeting to provide an opportunity for input from interested parties with regard to regulations for the expanded registry and results data bank.
• Public Meeting Information – detailed information about the meeting held at NIH on April 20, 2009

Additional Information

To receive occasional email announcements with information about US Public Law 110-85, join the
NIH FDAAA Update LISTSERV.

For specific questions or comments as this relates to the PRS, contact us at register@clinicaltrials.gov.

This page was last updated October 27, 2009.

U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894

National Institutes of Health, Department of Health & Human Services

Copyright and Privacy Policy, Freedom of Information Act, Accessibility